We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 15.00 | 0.85% | 1,789.00 | 1,797.00 | 1,798.00 | 1,801.00 | 1,769.00 | 1,792.00 | 1,087,265 | 16:35:03 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 2.88B | 192M | 0.8685 | 20.70 | 3.98B |
From Apr 2019 to Apr 2024
TIDMHIK
RNS Number : 2852S
Hikma Pharmaceuticals Plc
07 July 2020
Hikma Finance USA LLC
Publication of Offering Circular
7 July 2020
Hikma Finance USA LLC (the "Issuer") announces today that it has published an offering circular dated 7 July 2020 (the "Offering Circular") in connection with the issuance of US$500,000,000 3.250 per cent. Guaranteed Notes due 2025 (the "Notes") guaranteed by Hikma Pharmaceuticals PLC, Al Jazeerah Pharmaceutical Industries Ltd, Arab Pharmaceutical Manufacturing PSC, Eurohealth (U.S.A.), Inc., Hikma Farmacêutica (Portugal) S.A., Hikma Injectables USA Inc., Hikma Labs Inc., Hikma Pharma S.A.E., Hikma Pharmaceuticals International Limited, Hikma Pharmaceuticals LLC, Hikma Pharmaceuticals USA Inc., Hikma Specialty USA Inc. and West-Ward Columbus Inc.
The Notes are expected to be admitted to trading on the International Securities Market of the London Stock Exchange on or about 10 July 2020.
The Offering Circular is available for viewing.
To view the Offering Circular please paste the following URL into the address bar of your browser:
http://www.rns-pdf.londonstockexchange.com/rns/2852S_1-2020-7-7.pdf
Enquiries and Investor Relations
Susan Ringdal EVP, Strategic Planning and Global Affairs +44 (0) 20 7399 2760 / +44 7776 477050
LEI: 213800BU7YH2WTM1QL87
Regulated Information Classification: Additional regulated information required to be disclosed under the laws of a Member State
DISCLAIMER - INTENDED ADDRESSEES
Please note that the information contained in the Offering Circular may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Offering Circular) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Offering Circular is not addressed. Prior to relying on the information contained in the Offering Circular, you must ascertain from the Offering Circular whether or not you are one of the intended addressees of the information contained therein.
Your right to access this service is conditional upon complying with the above requirement.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
CIRKKOBQDBKDAOK
(END) Dow Jones Newswires
July 07, 2020 07:48 ET (11:48 GMT)
1 Year Hikma Pharmaceuticals Chart |
1 Month Hikma Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
